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Objectives The goal of this study was to make a head-to-head comparison of 2 common forms of multidisciplinary chronic
heart failure (CHF) management.
Background Although direct patient contact appears to be best in delivering CHF management overall, the precise form to
optimize health outcomes is less clear.
Methods This prospective, multicenter randomized controlled trial with blinded endpoint adjudication comprised 280 hos-
pitalized CHF patients (73% male, age 71  14 years, and 73% with left ventricular ejection fraction 45%)
randomized to home-based intervention (HBI) or specialized CHF clinic–based intervention (CBI). The primary
endpoint was all-cause, unplanned hospitalization or death during 12- to 18-month follow-up. Secondary end-
points included type/duration of hospitalization and healthcare costs.
Results The primary endpoint occurred in 102 of 143 (71%) HBI versus 104 of 137 (76%) CBI patients (adjusted hazard
ratio [HR]: 0.97 [95% confidence interval (CI): 0.73 to 1.30], p  0.861): 96 (67.1%) HBI versus 95 (69.3%) CBI
patients had an unplanned hospitalization (p  0.887), and 31 (21.7%) versus 38 (27.7%) died (p  0.252). The
median duration of each unplanned hospitalization was significantly less in the HBI group (4.0 [interquartile
range (IQR): 2.0 to 7.0] days vs. 6.0 [IQR: 3.5 to 13] days; p  0.004). Overall, 75% of all hospitalization was
attributable to 64 (22.9%) patients, of whom 43 (67%) were CBI patients (adjusted odds ratio: 2.55 [95% CI:
1.37 to 4.73], p  0.003). HBI was associated with significantly fewer days of all-cause hospitalization (35%;
p  0.003) and from cardiovascular causes (37%; p  0.025) but not for CHF (24%; p  0.218). Conse-
quently, healthcare costs ($AU3.93 vs. $AU5.53 million) were significantly less for the HBI group (median:
$AU34 [IQR: 13 to 81] per day vs. $AU52 [17 to 140] per day; p  0.030).
Conclusions HBI was not superior to CBI in reducing all-cause death or hospitalization. However, HBI was associated with signifi-
cantly lower healthcare costs, attributable to fewer days of hospitalization. (Which Heart failure Intervention is most
Cost-effective & consumer friendly in reducing Hospital care [WHICH?]; ACTRN12607000069459) (J Am Coll
Cardiol 2012;60:1239–48) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.025The burden of chronic heart failure (CHF), characterized by
costly hospitalization and poor survival, remains high (1,2).
Randomized trials in mid to late 1990s (3–6), confirmed by
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The WHICH? Trial October 2, 2012:1239–48prolong survival (7). These pro-
grams, built on the patient-
centered traditions of the chronic
care model developed by Wagner
and colleagues (8), can best be
described as a system of coordi-
nated healthcare interventions
specifically designed to optimize
the management of individuals
with CHF and where patient
self-care plays a vital role (9). As
the evidence evolves, 2 issues have
prompted substantial debate: the
need for direct (as against remote)
patient monitoring (10) and the
relationship between interven-
tional components and patient
outcomes (11). Although strong
arguments support direct patient
contact (4), the precise form of
ontact associated with optimal effects is less clear. The
HICH? (Which Heart Failure Intervention Is Most
ost-Effective & Consumer Friendly in Reducing Hospital
are) trial investigators envisaged there might be important
ifferences in the impact and acceptability (from a patient
erspective) of the 2 most popular forms of CHF-MP (12).
oth apply the same components of multidisciplinary care
ut via 2 very different settings: the first in the patient’s own
ome and the second via a specialist outpatient clinic. We
ypothesized that in typically older patients with CHF in
hom there are multiple factors contributing to poor
utcomes, a home-based approach would be more effective
n optimizing health outcomes due to a better overall
nderstanding of the patient and their environment. The
HICH? trial, therefore, tested the hypothesis that com-
ared to an equivalent clinic-based program of management,
nurse-led, post-discharge, multidisciplinary management
rogram for CHF patients age 45 years involving post-
ischarge home visits, will be superior in reducing the
omposite primary endpoint of unplanned (all-cause) read-
ission or death during 12 to 18 months follow-up. We
urther hypothesized that a home-based approach would
lso be more cost effective in reducing days of hospitaliza-
ion (12).
ethods
detailed description of the rationale and design of the
HICH? trial, a multicenter randomized controlled study,
as been published previously (12). It conformed to the
rinciples outlined in the Declaration of Helsinki and the
ONSORT (Consolidated Standards for Reporting Trials)
uidelines for pragmatic studies (13). All participants pro-
ided written informed consent. Undertaken in 3 Australian
ertiary referral hospitals, all centers had pre-existing CHF-
Abbreviations
and Acronyms
CBI  chronic heart failure
clinic–based intervention
CHF  chronic heart failure
CHF-MP  chronic heart
failure management
programs
CI  confidence interval
HBI  home-based
intervention
HR  hazard ratio
IQR  interquartile range
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
OR  odds ratioPs modified for the purpose of the trial and guided byardiologists experienced in CHF management (T.H.M.,
.M., and J.D.H.).
tudy endpoints. A blinded endpoint committee (S.S.,
.M., and C.R.) adjudicated on the type (elective vs.
nplanned) and cause of all hospitalizations. The primary
ndpoint was unplanned hospitalization or mortality (both
ll-cause) during 12 to 18 months of follow-up (study
ommenced June 2008, with census of outcome data March
1, 2011). As pre-specified in the index report (12), these
omposite events were also examined separately as: 1) a
roportion of affected individuals; and 2) in the case of
ospitalization, rate of hospitalization and duration of
ospitalization. We also examined event-free survival as
xpressed as “days alive out of hospital.” Pharmacological
herapy (including prescribed doses of angiotensin-
onverting enzyme [ACE] inhibitors and beta blockers) at
aseline and 12-month follow-up were also examined.
imilarly, health-related quality-of-life data were collected
sing generic (EQ-5D [14]) and CHF-specific instruments
Minnesota Living With Heart Failure Questionnaire
MLWHFQ] [15]) at 12 months to examine changes from
aseline (collected during the index admission). As also
re-specified, we prospectively collected health utilization
ata to perform an economic analysis of healthcare costs.
election criteria. All patients admitted to participating
enters were screened for study eligibility according to the
ollowing criteria: 1) age 18 years; 2) discharged to home
ith a diagnosis of CHF as confirmed by a cardiologist;
) persistent moderate-to-severe symptoms (New York
eart Association [NYHA] functional class II to IV); and
) a recent history of 1 admissions for acute heart failure.
Those excluded lived outside a 30-km radius of the hospital,
had a terminal condition, were non-English speaking,
and/or were unable to provide informed consent. As shown
in Figure 1 (study CONSORT flow chart [12]), of a total of
2,832 cardiac inpatients screened for eligibility, 298 (11%)
were randomized into the study. However, 18 patients died
or immediately withdrew consent from the study when
allocated to a particular intervention before discharge from
the index hospitalization and were excluded from subse-
quent analyses.
Randomization. Block randomization (computer-based at
independent site: Baker IDI) for each center, with stratifi-
cation for the presence/absence of left ventricular systolic
dysfunction, as determined by a left ventricular ejection
fraction (LVEF) of 45%, was applied on a 1:1 basis to
group assign patients.
Study data. Detailed demographic and clinical data were
collected at baseline (see Table 1 for indicative profiling in
a standardized manner by trained personnel). All surviving
patients were subject to clinical follow-up at 6 months (brief
telephone call), 12 months, and a final follow-up for up to
18 months (pre-scheduled home or clinic visit).
Post-discharge management. The key components and
principles of post-discharge management of CHF, either
delivered as an outreach, home-based intervention (HBI) or
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October 2, 2012:1239–48 The WHICH? Trialvia a clinic-based intervention (CBI) coordinated via a
specialist CHF outpatient clinic, according to contemporary
guidelines, have been extensively described (12). The Aus-
tralian healthcare system provides universal health care for
the population, with only minimal costs (capped for those
with chronic disease) for hospital treatment, pharmacother-
apy, and community care (including family physicians). The
study was designed to standardize the quality of manage-
ment (often supported by the same cardiologists and family
care physicians) but to vary how it was delivered, with
explicit acknowledgement that patient interaction with the
healthcare team would be modulated according to the mode
of management.
Briefly, HBI patients were scheduled to receive a home
visit by a trained CHF nurse within 7 to 14 days of hospital
discharge. This comprised a structured and detailed assess-
ment of the patient’s clinical stability, application of gold-
standard pharmacological and nonpharmacological manage-
ment, and any factors likely to positively or negatively
impact future health outcomes. Specific activities incorpo-
rated into this visit included: 1) a detailed clinical assess-
ment that included assessment of their cognitive status;
2) comprehensive assessment of the patient’s home environ-
Figure 1 CONSORT Diagram
A total of 723 eligible patients were identified, of which 280 were randomized
to the home-based intervention (n  143) and clinic-based intervention
(n  137). CHF  chronic heart failure.ment; 3) counseling of family members/care givers in the rhome; 4) detailed assessment of the patient’s social support
and coping skills; 5) review of the patient’s use of current
and past medication; 6) assessment of the patient’s food
supply (including supplementary salt intake) and fluid con-
sumption; 7) identification of key equipment (i.e., weight
scales); 8) determination of the patient’s level of mobility
and ease of access to local health services; 9) referral to a
community pharmacist for a comprehensive “home medi-
cines review” (16); and 10) close liaison with the patient’s
family physician. Subsequently, a report was sent to the
patient’s family physician and cardiologist, and planned
management (including telephone follow-up, referral to
other healthcare professionals, and additional home visits)
was arranged. Regardless of initial assessment, those dis-
charged to home following an unplanned hospitalization
were subject to re-evaluation of the relative success/failure of
management by the CHF nurse. Similarly, CBI patients
were scheduled to attend a post-discharge visit to the
nurse-led specialist CHF clinic where they had immediate
access to a multidisciplinary team including an experienced
cardiologist and pharmacist. The same principles of assess-
ment and follow-up as per HBI were applied. The key
differences being that for the CBI group, management was
primarily directed through the specialist CHF clinic on an
outpatient basis, and the patient did not receive a compre-
hensive home visit (see the preceding text). No restrictions
on access to other healthcare services were applied.
Statistical analyses. We estimated this study would have
80% power (2-sided alpha of 0.05) to detect a 15% absolute
difference in the primary endpoint in addition to a 15%
variation in the rate of all-cause hospital stay (in days) with
280 randomized patients; these thresholds were considered
to be of clinical significance and would generate statistical
differences in healthcare costs. All baseline and outcome
data were analyzed using SPSS for Windows version 19.0
(SPSS, Inc., Chicago, Illinois) on an intention-to-treat
basis. Continuous data are presented as a mean  SD or
edian plus interquartile range (IQR). Categorical data are
resented as a percentage. Univariate comparisons of base-
ine data involved chi-square analyses (with calculation of
dds ratios [ORs] and 95% confidence intervals [CIs]) for
ategorical data, the Mann-Whitney U test for non-
ormally distributed continuous data (including the rate of
ospital stay and healthcare costs), and the Student t test for
ormally distributed continuous data. All-cause mortality
nd event-free survival data were initially analyzed using
aplan-Meier survival curves. Days alive out of hospital
ere calculated as days of survival free from unplanned and
ll-cause hospitalization. Healthcare costs are calculated per
atient per day. All costs are expressed in 2009/2010
ustralian dollars (AU$1.00  US$1.00). To initially
xamine the independent impact of group allocation on:
) presence in the upper quartile group for most days of
e-hospitalization; 2) event-free survival; and 3) all-cause
rular fi
ociation
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The WHICH? Trial October 2, 2012:1239–48mortality, entry model multiple logistic regression and Cox
proportional hazards models were constructed. All models
included the variables listed in Table 1 (including age,
sex, cardiac function, and comorbidity) in addition to site
of recruitment (17). Backward, step-wise models (entry at
univariate level of p  0.1 and retention of variables at
adjusted level p  0.05) were then performed to deter-
mine the independent correlates of these outcomes.
Detailed methods of the health economics analysis (in-
cluding components of health expenditure—see Online
Baseline Characteristics According to Study AsTable 1 Baseline Characteristics According
All (N  280)
Demographic profile
Men 203 (73)
Age at entry, yrs 71 14
Living alone 155 (55)
12 years of education 54 (19)
Risk factor profile
Hypertension 177 (63)
History of smoking 194 (69)
BMI, kg/m2 28.3 6.9
Total cholesterol, mmol/l 3.9 1.3
Type 2 diabetes mellitus 109 (39)
CHF profile
Months since CHF diagnosis 39.6 63.7
LVEF, % 30.1 9.2
Preserved LV function 75 (27)
NYHA functional class II/III 238 (85)
Ischemic cardiomyopathy 159 (57)
Prior CHF admission (1 yr) 162 (58)
Index admission
Principal diagnosis of CHF 185 (66)
Length of stay, days 8.9 7.8
Coronary care unit, days 4.9 7.0
Clinical profile
Acute heart failure 134 (48)
Systolic blood pressure, mm Hg 116 22
Diastolic blood pressure, mm Hg 66 12
Heart rate, beats/min 73 12
eGFR, ml/min/1.73 m2 58.1 23.0
Hemoglobin, g/dl 12.8 1.9
Coronary artery disease 159 (57)
Atrial fibrillation 172 (61)
Comorbidity score* 6.2 2.4
Mild cognitive impairment 112 (40)
Depressive symptoms 98 (35)
Pharmacotherapy
ACE inhibitors or ARBs 213 (76)
Beta blockers 200 (71)
Spironolactone 109 (39)
Loop diuretic 232 (83)
Digoxin 90 (32)
Values are n (%) or median (interquartile range). For body mass inde
cognitive impairment, N  269 cases. *Charlson Index of Comorbidit
ACE  angiotensin-converting enzyme; ARB  angiotensin recept
intervention; CHF  chronic heart failure; eGFR  estimated glome
LVEF  left ventricular ejection fraction; NYHA  New York Heart AssTable 1) are provided in the Online Appendix.Results
Patients. Table 1 shows the baseline demographic and
clinical profile of this typically older study cohort (N 280)
with high levels of concurrent disease. There were more
men (73%) than women. On average, men were younger
(71  13 years vs. 73  14 years) and had more left
ventricular systolic dysfunction (LVEF: 34.4  13.4% vs.
42.9 15.8%; p 0.001). Overall, 254 (91%) patients were
prescribed an ACE inhibitor/angiotensin receptor blocker
ent (N  280)tudy Assignment (N  280)
HBI (n  143) CBI (n  137) p Value
104 (73) 99 (72) 0.931
70 15 73 13 0.046
80 (56) 75 (55) 0.746
32 (22) 22 (16) 0.520
93 (65) 84 (61) 0.519
97 (68) 97 (71) 0.590
28.6 7.8 28.0 5.8 0.537
4.0 1.3 3.9 1.3 0.765
51 (36) 58 (42) 0.252
34.6 55.3 44.8 71.0 0.200
30.2 9.8 30.0 8.4 0.865
35 (24) 40 (29) 0.534
118 (83) 120 (88) 0.235
78 (55) 81 (59) 0.257
85 (59) 77 (56) 0.584
101 (71) 84 (61) 0.100
8.2 7.4 9.5 8.1 0.169
5.4 7.3 4.4 6.6 0.419
69 (48) 65 (47) 0.146
117 23 116 21 0.883
66 12 67 12 0.602
74 12 73 13 0.436
58.8 23.2 57.3 22.9 0.708
12.9 2.0 12.8 1.8 0.928
78 (55) 81 (59) 0.257
83 (58) 89 (65) 0.143
5.9 2.5 6.5 2.3 0.055
56 (39) 56 (41) 0.695
57 (40) 41 (30) 0.082
110 (77) 103 (75) 0.632
104 (73) 96 (70) 0.626
55 (38) 54 (39) 0.870
116 (81) 116 (85) 0.627
44 (31) 46 (34) 0.615
246; lipid profile, N  119; time of CHF diagnosis, N  254; and for
(17).
er ; BMI  body mass index; CBI  chronic heart failure clinic–based
ltration rate; HBI  home-based intervention; LV  left ventricular;
.signmto S
x, N 
y Score
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October 2, 2012:1239–48 The WHICH? Trialdiuretic. Despite gold-standard therapy, 15% were in
NYHA functional class IV. Overall, the groups were fairly
well matched for all baseline parameters, with the notable
exception that HBI patients were, on average, 3 years
younger (p  0.046) and tended to have less comorbidity as
measured by the Charlson Index of Comorbidity.
Ambulatory contacts. More HBI patients (140 [98%])
received a home visit than CBI patients (124 [91%]) who
attended the specialist CHF clinic (OR: 1.08, 95% CI: 1.02
to 1.15; p  0.008). HBI patients also tended to have more
home visits than CBI patient appointments to the CHF
clinic (3.4  2.5 visits vs. 2.9  2.5 visits; p  0.061),
lthough CBI patients had, on average, 1 more cardiologic
utpatient visit overall. At the first visit or appointment,
ost patients were assessed as NYHA functional class II or
II (218 [83%]), 180 (68%) had orthopnea, 76 (29%)
eripheral edema, 45 (17%) a raised jugular venous pressure,
nd 32 (12%) had basal crackles. As expected, subsequent
eferrals to external multidisciplinary support were signifi-
antly greater for HBI than CBI patients (p  0.05 for all
omparisons), including referrals to a community-based
harmacist (39% vs. 18%), an exercise program (39% vs.
7%), and a dietician (16% vs. 10%). The same proportions
f patients (11%) were referred for urgent medical review to
ddress clinical instability. Similarly, 68% and 71% of HBI
nd CBI patients had planned telephone follow-up.
ollow-up home visits resulted in 10% of individuals requir-
ng immediate or emergency medical management due to
linical instability. The equivalent proportion in the CBI
roup (following a follow-up clinic visit) was 14%. Overall,
oth groups visited their family physician a similar number
f times (average 21 to 23 visits).
Subsequent telephone contact occurred in 122 (85%) and
13 (83%) of HBI and CBI patients, respectively; 43%
eceived 1 to 2 calls, and the remainder up to 19 calls. Of the
,063 telephone calls for patient management, 584 (55%)
ere routine clinical follow-up, 283 (27%) involved active
anagement (e.g., titrating pharmacotherapy), 111 (10%)
ere appointment reminders, and 85 (8%) were patient
nitiated. Overall, HBI patients received more calls (4.2 
.8 vs. 3.3  2.9; p  0.002) and were exposed to more
elephone management (39.9  41.0 min vs. 27.1  31.8
in; p  0.01).
harmacological management. A total of 96 HBI (67%)
atients and 85 CBI (62%) patients were clinically assessed
etween 12 and 18 months. More HBI patients received
old-standard therapy, but in lower doses. For example,
ore HBI patients were prescribed an ACE inhibitor
nd/or angiotensin receptor blocker (96% vs. 81%; p 
.002, OR: 1.18, 95% CI: 1.06 to 1.32), but CBI patients
ho were prescribed perindopril (the most commonly pre-
cribed ACE inhibitor) received higher daily doses (8.1 
.0 mg vs. 5.2  3.1 mg; p  0.001).
rimary endpoint. During study follow-up (mean of
7.4  1.4 months for surviving patients and 14.7  5.3
onths overall), unplanned hospitalization or death occurred hn 102 of 143 HBI patients (71%) compared with 104 of 137
BI patients (76%) patients (adjusted hazard ratio: 0.97, 95%
I: 0.73 to 1.30; p  0.861). Online Figure 1 shows the
djusted event-free survival curves for both groups.
ll-cause mortality. At 12 months, 56 patients (20%) died
comprising 18% of HBI and 22% of CBI patients). Figure 2
ompares the adjusted survival curves for the 2 groups on
he basis of 31 (22%) versus 38 (28%) deaths in the HBI and
BI groups, respectively, during total follow-up (adjusted
azard of risk: 0.75, 95% CI: 0.45 to 1.23; p  0.252). Of
ll 69 deaths, 7 (10%) were sudden cardiac events.
ecurrent hospitalization. The study cohort accumulated
74 and 615 unplanned and all-cause readmissions. This
ncluded 323 unplanned readmissions (68% of that category)
rimarily related to cardiovascular disease (including CHF).
verall, 96 (67%) HBI patients compared with 95 (69%) CBI
atients had 1 unplanned hospitalizations, with 60 (62%)
BI versus 52 (55%) CBI patients with multiple hospitaliza-
ions (p 0.194). The rate (per 100 days of follow-up/patient)
f unplanned and total hospitalization was similar in the HBI
roup compared with the CBI group, respectively. This trend
as also seen with respect to all cardiovascular and CHF-
pecific hospitalizations (Fig. 3).
ays of hospitalization. A total of 3,744 unplanned and
,430 days of recurrent unplanned hospitalization were
ccumulated during study follow-up. Average length of
ospital stay for all-cause, unplanned hospitalization was
ignificantly lower (p  0.004) in the HBI group (median:
.0, IQR: 2.0 to 7.0 days vs. 6.0, IQR: 3.5 to 13 days). A
imilar, but nonsignificant, trend (p  0.674) was observed
n relation to elective hospitalization (median: 2.0, IQR: 1.0
o 5.0 vs. 6.0, IQR: 1.0 to 14). Figure 3 compares the rate
f hospitalization and days of hospitalization for the 2
roups. As such, after adjusting for survival and follow-up,
BI patients accumulated fewer days of unplanned (668
ays [31%] less; p  0.059) and total hospitalization (938
ays [34%] less; p  0.003) than CBI patients. Group
ifferences extended to cardiovascular-related days of hos-
italization (2,628 days representing 59% of all hospitaliza-
ion) and those directly attributable to CHF (1,845 days
epresenting 70% of cardiovascular-related hospitalization).
verall, HBI patients accumulated significantly fewer days of
ardiovascular-related hospitalization (588 days [37%] less;
 0.025) but not CHF-related hospitalization (257 days
24%] less; p  0.218).
Post-hoc analyses showed that the difference between
roups in days of hospitalization was largely attributable to
he 64 patients (22.9%) who accumulated 25 days of
ospitalization during study follow-up (the upper quartile
hreshold for accumulated days of hospitalization) and who
ccounted for 75% of such activity (Online Fig. 2). Overall,
3 of these 64 patients (67%) belonged to the CBI group.
hey were significantly older (77  10 years vs. 70  14
ears; p  0.001), had more preserved left ventricular
unction (LVEF: 40  13% vs. 35  15%; p  0.08), and
ad a longer index admission (11.1  8.7 days vs. 8.1  7.4
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The WHICH? Trial October 2, 2012:1239–48days; p 0.03) than the rest. On an adjusted basis, the only
independent predictors of prolonged hospital stay was
advancing age (OR: 1.06, 95% CI: 1.03 to 1.09 per year;
p  0.001) and allocation to CBI (OR: 2.55, 95% CI: 1.37
to 4.73; p  0.003).
ays alive out of hospital. There was a significant differ-
nce between groups regarding actual days out of hospital
from unplanned hospitalization) alive (452  158 days vs.
18  173 days; p  0.019) and all days out of hospital
elective plus unplanned hospitalization) alive (451  158
ays vs. 414  172 days; p  0.009) in favor of HBI. The
atter equated to 85% (11,869 days lost) versus 80% (14,248
ays lost) of maximal survival without hospitalization.
ealth-related quality of life. Baseline EQ-5D (0.76 
.18 vs. 0.77  0.18; p  0.921) and MLWHFQ scores
48.8  21.9 vs. 46.0  20.5; p  0.279) were similar for
BI and CBI patients; best and worst health states being
.0 and 0.0, respectively. Reflecting similar trends at 6
onths, among survivors with repeat scores at 12 months
87 HBI and 84 CBI patients), the mean changes in
Q-5D scores were not significantly different (0.136 
.363 vs. 0.183  0.350, respectively; p  0.305).
lternatively, MLWHFQ scores demonstrated improved
uality of life in both HBI and CBI patients (median
hange:10, IQR:30 to 1 vs. median change:12, IQR:
31 to 11, respectively; p  0.445). As there were no
ifferences between groups in EQ-5D scores or quality-
djusted life-years, a cost-minimization analysis was
Figure 2 Comparison of Adjusted Cumulative Survival During 1
Independent predictors of mortality were age (adjusted hazard ratio [HR]: 1.03, 95
to 4.17), length of index hospitalization (HR: 1.03, 95% CI: 1.01 to 1.06 per day),
estimated glomerular filtration rate).ppropriate. cealthcare costs. Table 2 summarizes the components
f healthcare costs per day for the 2 groups (AU$1.00 
S$1.00). Hospital costs accounted for 89% and 93% of
otal costs in the HBI and CBI groups, respectively, whereas
he cost of applying the specific HBI and CBI programs per
atient were similar AU$1,813  AU$220 and AU$1,829 
U$174 (representing 9.0% and 4.2% of total healthcare
osts). Overall, predominantly due to fewer days of hospi-
alization, total healthcare costs were around 30% lower in
he HBI group (AU$3.93 million vs. AU$5.53 million; p 
.03 for median costs per day).
iscussion
o our knowledge, this represents the first direct compari-
on of an outreach versus specialist clinic–based approach to
ost-discharge CHF management. We compared these
ommonly applied forms of CHF-MP in order to deter-
ine whether there were additional benefits derived from an
utreach CHF-MP in typically old and fragile patients
ischarged to home following acute hospitalization. Overall,
here was minimal difference with respect to the primary
ndpoint of (all-cause) death or unplanned readmission
uring 12 to 18 months of follow-up. Although, HBI had
better survival profile (6% absolute difference), this did not
each statistical significance. However, there were important
ifferences with respect to the cost impact of HBI. Reflect-
ng shorter episodes of hospitalization (the most costly
8 Months of Follow-Up
fidence interval [CI]: 1.00 to 1.06 per year), male sex (HR: 2.22, 95% CI: 1.18
mpaired renal function (HR: 0.99, 95% CI: 0.98 to 1.00, per unit decline in the2 to 1
% con
and iomponent of CHF management [18]), HBI patients
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October 2, 2012:1239–48 The WHICH? Trialaccumulated significantly fewer days of total all-cause (35%
days fewer) and cardiovascular-related hospitalization (37%
days fewer), with a consistent (borderline) trend with
respect to less unplanned hospitalization (30% days
fewer). HBI was also associated with a nonsignificant
reduction in CHF stay. Combined, this resulted in
significantly more prolonged days out of hospital alive in
favor of HBI. Consequently, total healthcare costs were
nearly one-third less within the HBI group. The combi-
nation of greater uptake of HBI overall, a more favorable
profile free from hospitalization and death, and more
favorable cost dynamics (largely mediated through a
greater reduction in non-CHF–related hospitalization)
are of clinical and public health significance. Although
the primary endpoint was not statistically different, there-
fore, these data now provide a potentially important
delineation between the 2 most utilized forms of face-
Figure 3 Comparison of Rate of All-Cause Admissions, All-Caus
Home-based intervention (HBI) versus CHF clinic–based intervention (CBI) compar
[IQR]]: 0.36 [0.18 to 0.73] vs. 0.36 [0.18 to 0.91]) and unplanned admissions (m
sions (median [IQR]: 0.18 [0.0 to 0.39] vs. 0.18 [0.0 to 0.55]) and CHF admissio
(median [IQR]: 0.91 [0.18 to 4.1] vs. 2.1 [0.18 to 8.9]) and unplanned days (med
(median 95% CI: 0.20 [0.0 to 1.9] vs. 0.70 [0.0 to 4.6]) and CHF-related days (medto-face CHF-MP.Study validity. A number of aspects about the validity and
wider applicability of the trial require consideration. First,
similar to many contemporary CHF-MP trials, the standard
of gold-standard pharmacotherapy was high. This is per-
haps reflected in the relatively low mortality rates in high-
risk patients (with high comorbidity) countered by high
levels of morbidity (40% had multiple unplanned readmis-
sions) and recurrent hospital stay. The WHICH? trial
cohort is similar in age and sex profile to the COACH
(Coordinating Study Evaluating Outcomes of Advising and
Counseling in Heart Failure) study reported by Jaarsma et
al. (19), but with higher levels of concurrent coronary artery
disease, atrial fibrillation, and stroke. Although a similar
proportion of patients were re-admitted for CHF (around
40%), our cohort had greater levels of recurrent, all-cause
hospital stay. Despite this, case fatality was comparable, if
not lower, than that reported by the COACH investigators
y, CV-Related Admissions, and CV-Related Stay
er 100 days/patient: (A) all-cause admissions (median [interquartile range
[IQR]: 0.20 [0.0 to 0.55] vs. 0.23 [0.0 to 0.82]); (C) cardiovascular (CV) admis-
dian [IQR]: 0.0 [0.0 to 0.20] vs. 0.0 [0.0 to 0.36]); (B) all-cause days of stay
R]: 0.70 [0.0 to 3.7] vs. 1.3 [0.0 to 6.6]); and (D) CV-related days of stay
R]: 0.0 [0.0 to 1.5] vs. 0.0 [0.0 to 3.1]). Abbreviations as in Figures 1 and 2.e Sta
isons p
edian
ns (me
ian [IQ
ian [IQ(19) and in a recent trial of a brain natriuretic peptide–
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The WHICH? Trial October 2, 2012:1239–48guided CHF-MP versus a standard CHF-MP and usual
care (20). Nevertheless, case fatality and morbidity rates
remain high, and efforts to enhance the efficacy of CHF-
MPs, either through biomarker-guided therapy (20) or
upplementary remote monitoring techniques, (21) remain a
riority. The Australian healthcare system (while reflecting
hybrid version of universal healthcare and a user-pay
ystem) provided a strong platform to compare 2 different
orms of CHF-MP. With the exception of access to the
HF clinic (CBI group) and home visits (HBI), patients in
oth groups had access to the same healthcare professionals
including cardiologists and family physicians). This envi-
onment enabled us to standardize the level and qualities of
are provided, and observe critical differences in patient
ourneys according to the mode of CHF-MP applied.
espite potentially important baseline differences in patient
rofile (particularly more advanced age and comorbidity in
he CBI group), we were able to demonstrate that the
ritical difference between groups with respect to “high-
ost” users of health care (two-thirds of whom were CBI
atients) was independently influenced by group allocation.
otential benefits of HBI. It is important to emphasize
Cost of Health According to Study Assignment ($AU)Table 2 Cost of Health According to Study Assignment ($AU)
Component of Cost/Patient All (N  280)
Days of follow-up 444 164
548 [396–548]
Total hospital costs $28,581 $48,313
$12,439 [$883–$34,904]
($22,897–$34,264)
Elective admission $5,222 $14,890
$0 [$0–$1,288]
($3,470–$6,973)
Unplanned admission $23,359 $45,352
$4,326 [$0–$29,515]
($18,023–$28,694)
Per diem costs $25,886 $46,578
$7,220 [$722-$30,766]
($20,407–$31,365)
Procedural costs $2,695 $4,632
$819 [$160–$2,499]
($2,150–$3,240)
Cost of intervention $1,821 $199
$1,825 [$1,812–$1,844]
($1,798–$1,844)
Other community costs $3,374 $1,380
$3,545 [$2,858–$4,247]
($3,212–$3,536)
Total health care costs $33,775 $48,342
$15,650 [$6,537–$39,412]
($28,088–$39,462)
Cost per day of follow-up $119 $247
$41 [$13–$107]
($90–$148)
Values are mean  SD or median [interquartile range] and (95% confidence interval).
CHF  chronic heart failure.hat the primary endpoint of unplanned hospitalization or meath was not statistically different between groups and that
his was, perhaps, an optimistic composite endpoint in that
t relied on delaying and even preventing events. On an
djusted basis, there was little difference between the 2
orms of CHF-MP, most probably reflecting high standards
f initial post-discharge management. The mechanism(s)
nderlying the apparent longer-term benefits of HBI with
espect to a significant reduction in “high-cost” patients
ith more prolonged hospitalization, as always, are difficult
o elucidate. Consistent with the overall benefits associated
ith the application of HBI in chronic disease management
including reduced healthcare costs [18]), there are a num-
er of factors that may explain our findings. First, as
ndicated by the frequency and duration of patient contacts,
he HBI group appeared to be more engaged and more
ikely, therefore, to benefit from the expert management on
ffer. This resulted in a greater number of referrals. By its
ery nature (i.e., visiting patients and significant others in
heir own homes), HBI has the potential to provide a more
ccurate assessment of a patient’s overall clinical and psy-
hosocial status and, critically, their ability to self-care. This
n turn would facilitate more specific and tailored manage-
Home-Based (n  143) CHF Clinic (n  137)
458 158 431 169
548 [426–548] 548 [368–548]
$22,236 $39,442 $35,203 $55,476
$8,592 [$849–$30,749] $14,595 [$1,299–$40,864]
($15,716–$28,756) ($25,830–$44,576)
$3,727 $10,255 $6,782 $18,446
$0 [$0–$1,287] $0 [$0–$1,299]
($2,032–$5,422) ($3,666–$9,899)
$18,509 $36,797 $28,421 $52,490
$3,311 [$0–$25,742] $6,773 [$0–$31,773]
($12,426–$24,592) ($19,552–$37,289)
$19,705 $37,940 $32,338 $53,532
$5,054 [$722–$26,019] $10,830 [$722–$37,424]
($13,433–$25,976) ($23,293–$41,382)
$2,531 $4,375 $2,865 $4,896
$807 [$127–$2,245] $876 [$232–$2,711]
($1,808–$3,255) ($2,038–$3,692)
$1,813 $220 $1,829 $174
$1,827 [$1,813–$1,844] $1,823 [$1,810–$1,844]
($1,777–$1,850) ($1,800–$1,858)
$3,436 $1,323 $3,308 $1,439
$3,630 [$2,952–$4,230] $3,399 [$2,725–$4,277]
($3,218–$3,655) ($3,065–$3,552)
$27,486 $39,638 $40,340 $55,395
$13,088 [$6,440–$6,978] $18,926 [$6,978–$46,841]
($20,933–$34,038) ($30,981–$49,700)
$90 $200 $149 $285
$34 [$13–$81] $52 [$17–$140]
($57–$123) ($101–$197)ent (including pharmacotherapy) for a cohort of patients
(
c
t
p
a
e
e
m
m
p
d
t
a
i
m
m
C
I
d
C
c
f
r
m
r
c
c
h
T
r
i
s
t
m
1247JACC Vol. 60, No. 14, 2012 Stewart et al.
October 2, 2012:1239–48 The WHICH? Trialwith complex needs, and therefore, lead to greater clinical
stability (as reflected in the fewer days of hospitalization).
The more “generic” approach to chronic disease manage-
ment, as applied by the multidisciplinary HBI team, would
be expected to have a broader impact on non-CHF–related
health outcomes. Observed differences in all-cause and
cardiovascular-related hospital stay in favor of HBI support
this supposition. It is certainly feasible that patients simply
prefer and respond better to a health intervention that
appears to be more flexible to their needs: our prospectively
planned analyses of health delivery preferences in this cohort
(22) will further elucidate potential differences from a
consumer perspective. Finally, we cannot discount the
possibility that HBI patients were discharged earlier on the
premise that extended hospital days could be replaced by
increased home surveillance (despite not being a “hospital in
the home” program).
Study limitations. As discussed in our methods report
12), there are a number of limitations, including the
onfounding effect of patient (and potentially healthcare
eam) bias in favor of a particular CHF-MP. Wherever
ossible, we minimized contamination between groups, and
ll endpoints were subject to blinded adjudication. Type II
rror cannot be ruled out with respect to our ability to
xamine a definitive difference with respect to all-cause
ortality. As discussed, it was impractical to fully explore
echanisms of effect, and we cannot fully discount the
ossibility that observed differences were due to important
ifferences in the quality of care, nor can we fully discount
he influence of observed baseline differences in the age
nd clinical profile of the 2 groups. Moreover, it is
mportant to consider the potential cost dynamics of
ore prolonged survival and exposed risk to greater
orbidity in survivors (23).
onclusions
n this prospective, multicenter, randomized trial of multi-
isciplinary CHF management delivered via an HBI versus
BI approach, we found no difference in unplanned (all-
ause) hospitalization or death during 12- to 18-month
ollow-up. However, HBI was associated with a significant
eduction in the duration of recurrent hospitalization and
ore prolonged survival free from hospitalization that
esulted in an important delineation between the 2 most
ommonly applied forms of CHF-MP. Ultimately, this
ontributed to an approximate one-third reduction in
ealthcare costs in favor of the outreach HBI program.
he fact that we observed the greatest differences with
espect to all-cause and cardiovascular-related hospital-
zation in this typically older cohort of CHF patients
uggests that the benefits of a more generic hospital
ransition program involving home visits outweigh a
ore CHF-specific focus.Acknowledgments
The authors thank all the cardiac nurses, healthcare
professionals, and patients who participated; and Alicia
Calderone and the staff at Baker IDI who contributed to
data management.
Reprint requests and correspondence: Dr. Simon Stewart, Pre-
ventative Health, Baker IDI Heart and Diabetes Institute, P.O.
Box 6492, St. Kilda Road Central, Melbourne, Victoria 8008,
Australia. E-mail: simon.stewart@bakeridi.edu.au.
REFERENCES
1. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional
trends in heart failure hospitalization and mortality rates for Medicare
beneficiaries, 1998–2008. JAMA 2011;306:1669–78.
2. Stewart S, Ekman I, Ekman T, Oden A, Rosengren A. Population
impact of heart failure and the most common forms of cancer: a study
of 1,162,309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc
Qual Outcomes 2010;3:573–80.
3. Cline CM, Israelsson BY, Willenheimer RB, Broms K, Erhardt LR.
Cost effective management programme for heart failure reduces
hospitalisation. Heart 1998;80:442–6.
4. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE,
Carney RM. A multidisciplinary intervention to prevent the readmis-
sion of elderly patients with congestive heart failure. N Engl J Med
1995;333:1190–5.
5. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary,
home-based intervention on unplanned readmissions and survival
among patients with chronic congestive heart failure: a randomised
controlled study. Lancet 1999;354:1077–83.
6. Blue L, Lang E, McMurray JJ, et al. Randomised controlled trial of
specialist nurse intervention in heart failure. BMJ 2001;323:715–8.
7. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary
strategies for the management of heart failure patients at high risk for
admission: a systematic review of randomized trials. J Am Coll Cardiol
2004;44:810–9.
8. Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the
Chronic Care Model in the new millennium. Health Aff (Millwood)
2009;28:75–85.
9. Windham BG, Bennett RG, Gottlieb S. Care management interven-
tions for older patients with congestive heart failure. Am J Manag Care
2003;9:447–59.
10. Inglis SC, Clark RA, McAlister FA, Stewart S, Cleland JGF. Which
components of heart failure programmes are effective? A systematic
review and meta-analysis of the outcomes of structured telephone
support or telemonitoring as the primary component of chronic heart
failure management in 8323 patients: Abridged Cochrane Review. Eur
J Heart Fail 2011;13:1028–40.
11. Clark AM, Savard LA, Thompson DR. What is the strength of
evidence for heart failure disease-management programs? J Am Coll
Cardiol 2009;54:397–401.
12. Stewart S, Carrington MJ, Marwick T, et al. The WHICH? trial:
rationale and design of a pragmatic randomized, multicentre compar-
ison of home- vs. clinic-based management of chronic heart failure
patients. Eur J Heart Fail 2011;13:909–16.
13. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting
of pragmatic trials: an extension of the CONSORT statement. BMJ
2008;337:a2390.
14. Viney R, Norman R, King MT, et al. Time trade-off derived EQ-5D
weights for Australia. Value Health 2011;14:928–36.
15. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living
with Heart Failure questionnaire as a measure of therapeutic response
to enalapril or placebo. Am J Cardiol 1993;71:1106–7.
16. Barker A, Barlis P, Berlowitz D, Page K, Jackson B, Lim WK.
Pharmacist directed home medication reviews in patients with
chronic heart failure: a randomised clinical trial. Int J Cardiol 2012;
159:139 – 43.
22
1248 Stewart et al. JACC Vol. 60, No. 14, 2012
The WHICH? Trial October 2, 2012:1239–4817. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: develop-
ment and validation. J Chronic Dis 1987;40:373–83.
18. Stewart S, Blue L, Walker A, Morrison C, McMurray JJ. An
economic analysis of specialist heart failure nurse management in
the UK: can we afford not to implement it? Eur Heart J 2002;23:
1369 –78.
19. Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of
moderate or intensive disease management program on outcome in
patients with heart failure: Coordinating Study Evaluating Outcomes
of Advising and Counseling in Heart Failure (COACH). Arch Intern
Med 2008;168:316–24.
20. Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic
peptide-guided, intensive patient management in addition to multi-
disciplinary care in chronic heart failure: a 3-arm, prospective, ran-
domized pilot study. J Am Coll Cardiol 2010;55:645–53.21. Gaikwad R, Warren J. The role of home-based information and
communications technology interventions in chronic disease manage-ment: a systematic literature review. Health Informatics J
2009;15:122–46.
2. Whitty JA, Carrington MJ, Stewart S, Holliday J, Marwick T,
Scuffham PA. Patient preferences for the delivery of disease manage-
ment in chronic heart failure: a qualitative study. J Cardiovasc Nurs
2012;27:201–7.
3. Inglis SC, Pearson S, Treen S, Gallasch T, Horowitz JD, Stewart S.
Extending the horizon in chronic heart failure: effects of multidisci-
plinary, home-based intervention relative to usual care. Circulation
2006;114:2466–73.
Key Words: disease management y health economics y heart failure.
APPENDIX
For detailed methods and supplemental table and figures,
please see the online version of this article.
